Former Chief Technology Officer · Vir Biotechnology, Inc. (VIR)

Michael Kamarck

FY2020 is the first fiscal year CompBrief holds for Michael Kamarck as a named executive officer of Vir Biotechnology; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$803,800

Salary $426,400Stock awards $0

5th of 5 named executive officers at Vir Biotechnology by FY2020 total.

5 named officers on file for Vir Biotechnology, FY2020

Michael Kamarck’s pay file — $29

  • 1 fiscal year of pay, line by line
  • VIR’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vir Biotechnology’s whole pay program stands against its peers

  • Vir Biotechnology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VIR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 6, 2021 (DEF 14A).

Free

Get Michael Kamarck’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael Kamarck compensation by year

Vir Biotechnology Summary Compensation Table · the one fiscal year held
In US dollars, as Vir Biotechnology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$426,400
Bonus$0
Stock awards$0
Option awards$0
Non-equity incentive$266,000
Pension and deferred compensation$0
All other$111,400
Total$803,800

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vir Biotechnology, Inc. DEF 14A filed April 6, 2021, accession 0001193125-21-107570, and prior-year filings.

How this page was built: the Vir Biotechnology, Inc. filed document, accession 0001193125-21-107570. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2021.

Vir Biotechnology’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Steven RiceChief Administrative Officer$2,174,859
Howard HornChief Financial Officer$1,642,019
Herbert VirginExecutive Vice President, Research and Chief Scientific Officer$1,106,236
George ScangosPresident and Chief Executive Officer$994,883
Michael Kamarck · this pageFormer Chief Technology Officer$803,800

The full Vir Biotechnology compensation record

free company brief

This page is one person within Vir Biotechnology's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vir Biotechnology proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vir Biotechnology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Kamarck's compensation dossier · One-time report. No refunds.